Posting Date: October 20, 2021

Closing Date: October 30, 2021 11:30 a.m. ET

Reference Number: 22-002624

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

At the National Cancer Institute (NCI), The Laboratory of Pathology (LP) is an integral component of the research and clinical community. Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education. We support the research mission of the NCI by investigating the biology and genetics of cancer and other diseases, developing and applying leading edge technology to diagnostic pathology, providing collaborative support for clinical research protocols in this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles.

The primary objective of the service agreement purpose is to guarantee timely maintenance and repair service for the Benchmark XT. This service is required through the manufacturer of said equipment for continued service to our facility to maintain the highest level of accuracy and equipment performance.

The National Cancer Institute plans to purchase Service Agreement for Benchmark Ultra (S/N: 313421) from Roche Diagnostics. This is nota request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on October 30, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

All tests performed in our laboratory have been comprehensively validated based on CLIA and CAP regulations for clinical uses. Regulatory oversight requires development of Standard Operating Procedures (SOP) using defined reagents and equipment and include SOPs for maintenance of all equipment. This instrument is a key component for nearly 1/3 of our assays, and its continuous functioning at peak performance levels is essential to our clinical effort and a maintenance contract is required to maintain laboratory accreditation. To maintain the highest standard performance, complex scientific instruments are required to be maintained and serviced by the original manufacturer. Original manufacturer service is required to avoid nullifying the warranty. Any equipment failure would adversely affect NCI/NIH clinical center patients and their optimal care.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request